Structural basis for the inhibition of HKU8 main protease by nirmatrelvir and ensitrelvir
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2026.154390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Mengmeng Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, Shanghai Tech University, Shanghai, China; College …. Hauptthemen laut MEDLINE: Antiviral Agents, Protease Inhibitors, Viral Nonstructural Proteins, Betacoronavirus. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Chongqing Municipal Science and Technology Bureau, National Natural Science Foundation of China.
Abstract (Originalsprache)
The wide distribution and high divergence of zoonotic coronaviruses (CoVs) poses a continuous threat to public health. Some CoVs, such as HKU8, harbor a high potential to breach the species barrier and emerge in human populations. However, whether the current antivirals are effective against HKU8 CoV remains poorly understood. Here, we studied the effectiveness of two clinically approved antivirals, nirmatrelvir and ensitrelvir, against the main protease (Mpro) of the HKU8. Both nirmatrelvir and ensitrelvir can inhibit HKU8 Mpro, but their efficacy is attenuated by approximately 5-fold and 15-fold, respectively, compared to their activity against SARS-CoV-2 Mpro. To elucidate the structural basis of this reduced potency, crystal structures of HKU8 Mpro in complex with nirmatrelvir and ensitrelvir were determined at 2.43 Å and 1.70 Å resolution, respectively. The HKU8 Mpro features a proline at position 188 instead of the characteristic 310-helix found in beta-CoVs. This difference results in a reduced volume of this subsite, which may lead to suboptimal binding of both inhibitors and reduced efficacy. These findings provide crucial information on the effectiveness of Mpro-targeting antivirals cross different species and highlight the S2 subsite as a key determinant for their activity. It may help the design of next-generation broad-spectrum antivirals against CoVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, Shanghai Tech University, Shanghai, China; College of Pharmacy, Chongqing Medical University, Chongqing, China.
- Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, Shanghai Tech University, Shanghai, China.
- School of Life Sciences, Tianjin University, Tianjin, 300072, China.
- MOE Key Laboratory of Cellular Physiology and Department of Physiology, Shanxi Medical University, Taiyuan, China; SXMU-Tsinghua Collaborative Innovation Center for Frontier Medicine, Shanxi Medical University, Taiyuan,…
Förderung
- Chongqing Municipal Science and Technology Bureau
- National Natural Science Foundation of China
Zitieren
APA
Lin, M., Zeng, X., Xiao, Y., Zhang, M., Li, D., & Wang, D. (2026). Structural basis for the inhibition of HKU8 main protease by nirmatrelvir and ensitrelvir. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.154390
Vancouver
Lin M, Zeng X, Xiao Y, Zhang M, Li D, Wang D. Structural basis for the inhibition of HKU8 main protease by nirmatrelvir and ensitrelvir. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.154390
BibTeX
@article{Lin2026,
author = {Lin, Mengmeng and Zeng, Xudong and Xiao, Yunjie and Zhang, Meng and Li, Dong and Wang, Deping},
title = {Structural basis for the inhibition of HKU8 main protease by nirmatrelvir and ensitrelvir},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2026.154390}
}
EUVIMED